Hamburg-based Evotec, a drug discovery alliance and development partnership company, has announced a $23.8 million gift over five years from the Bill and Melinda Gates Foundation in support of new treatment regimens for tuberculosis.
In 2017, ten million people fell ill with tuberculosis, the leading cause of death due to infectious disease globally. Current TB treatment necessitates four separate drugs administered under direct supervision over six months — longer when the disease is drug resistant. With the goal of developing treatment regimens that are safer, shorter, and more effective than the current standard, the grant will provide the means for standardized, high-quality pre-clinical data to support novel TB treatment regimen selection and development.
"We are honored to join with the Bill & Melinda Gates Foundation to fight tuberculosis, one of the world's most deadly infectious diseases," said Evotec CEO Werner Lanthaler. "With our contributions of industrialized, high-quality infrastructure and innovative methodology, we are confident that this combined international effort is the best possible starting point to bring huge benefits to the large number of patients who suffer from TB around the globe."